Eurobio Scientific SA
PAR:ALERS

Watchlist Manager
Eurobio Scientific SA Logo
Eurobio Scientific SA
PAR:ALERS
Watchlist
Price: 25.65 EUR 7.55%
Market Cap: 256.6m EUR

EV/EBITDA
Enterprise Value to EBITDA

8.6
Current
5.5
Median
4.1
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
8.6
=
Enterprise Value
249.3m EUR
/
EBITDA
29m EUR
Market Cap EV/EBITDA
FR
Eurobio Scientific SA
PAR:ALERS
257.2m EUR 8.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -212 079.3
US
Abbvie Inc
NYSE:ABBV
357.9B USD 16.6
US
Amgen Inc
NASDAQ:AMGN
164.2B USD 16.2
US
Gilead Sciences Inc
NASDAQ:GILD
138.5B USD 11.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.1B USD 26.4
US
Epizyme Inc
F:EPE
94.1B EUR -532.7
AU
CSL Ltd
ASX:CSL
121.8B AUD 17.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.7B USD 10.2
US
Seagen Inc
F:SGT
39.3B EUR -60.9
NL
argenx SE
XBRU:ARGX
33B EUR 315.4
EBITDA Growth EV/EBITDA to Growth
FR
Eurobio Scientific SA
PAR:ALERS
Average EV/EBITDA: 52.7
8.6
10%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 079.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.2
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
NL
argenx SE
XBRU:ARGX
315.4
166%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
8.9
2-Years Forward
EV/EBITDA
7.7
3-Years Forward
EV/EBITDA
6.4